15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $20.1B | $2.9B | 69.0% | 18.0% | $3.7B | — | $2.0B |
| 2024 | $16.7B | $1.8B | 68.6% | 15.5% | $2.6B | — | $414M |
| 2023 | $14.2B | $1.6B | 69.5% | 16.5% | $1.8B | — | $865M |
| 2022 | $12.7B | $698M | 68.8% | 13.0% | $938M | — | $928M |
| 2021 | $11.9B | $1.0B | 68.8% | 10.1% | $1.3B | — | $1.9B |
| 2020 | $9.9B | -$82M | 65.0% | -0.8% | $1.1B | — | $1.7B |
| 2019 | $10.7B | $4.7B | 71.0% | 14.1% | $1.4B | — | $217M |
| 2018 | $9.8B | $1.7B | 71.4% | 15.3% | -$6M | — | $146M |
| 2017 | $9.0B | $104M | 71.3% | 14.2% | $1.1B | $3.8B | $188M |
| 2016 | $8.4B | $347M | 71.1% | 5.3% | $806M | $5.4B | $196M |
| 2015 | — | -$239M | — | — | $444M | $5.7B | $319M |
| 2014 | — | -$119M | — | — | $1.0B | $4.2B | $587M |
| 2013 | — | -$121M | — | — | $865M | $4.2B | $217M |
| 2012 | — | -$4.1B | — | — | $1.1B | $4.2B | $207M |
| 2011 | — | $441M | — | — | $704M | $4.2B | $267M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $5.2B | $1.3B | 69.5% | 21.2% | $171M | — | $1.5B |
| Dec '25 | $5.3B | $670M | 69.6% | 15.6% | $1.0B | — | $2.0B |
| Sep '25 | $5.1B | $755M | 69.9% | 20.7% | $1.2B | — | $1.3B |
| Jun '25 | $5.1B | $795M | 67.7% | 16.2% | $1.1B | — | $534M |
| Mar '25 | $4.7B | $672M | 68.8% | 19.8% | $354M | — | $725M |
| Dec '24 | $4.6B | $562M | 67.9% | 14.8% | $1.2B | — | $414M |
| Sep '24 | $4.2B | $468M | 68.8% | 17.4% | $823M | — | $2.5B |
| Jun '24 | $4.1B | $322M | 69.2% | 12.6% | $658M | — | $2.9B |
| Mar '24 | $3.9B | $493M | 68.7% | 17.5% | -$15M | — | $2.3B |
| Dec '23 | $3.7B | $504M | 69.2% | 15.7% | $690M | — | $865M |
| Sep '23 | $3.5B | $504M | 68.8% | 19.6% | $508M | — | $952M |
| Jun '23 | $3.6B | $270M | 70.6% | 14.3% | $515M | — | $426M |
| Mar '23 | $3.4B | $314M | 69.3% | 16.3% | $79M | — | $570M |
| Dec '22 | $3.2B | $140M | 68.8% | 12.4% | $595M | — | $928M |
| Sep '22 | $3.2B | $188M | 69.1% | 11.3% | $320M | — | $338M |
| Jun '22 | $3.2B | $260M | 68.8% | 13.0% | $202M | — | $276M |
| Mar '22 | $3.0B | $110M | 68.4% | 15.4% | -$179M | — | $325M |
| Dec '21 | $3.1B | $95M | 68.9% | 5.8% | $212M | — | $1.9B |
| Sep '21 | $2.9B | $419M | 69.3% | 13.2% | $358M | — | $1.9B |
| Jun '21 | $3.1B | $186M | 69.3% | 8.5% | $537M | — | $2.7B |
How the market has priced BSX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Boston Scientific's revenue has grown 15.2% per year. These are computed facts, not advice.
As of FY2025, Boston Scientific reported — of total debt against $2.0B of cash; operating income covered interest expense 10×.
In FY2025, gross margin was 69.0%, operating margin 18.0%, and net margin 14.4%.
As of Jun '26, Boston Scientific traded at a price-to-earnings ratio of about 22.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.